FDA


  • A photo of a sign showing the Food and Drug Administration logo
    Image attribution tooltip
    Sarah Silbiger via Getty Images

    MEI, Kyowa stop lymphoma drug trials after FDA meeting

    The decision not to run a Phase 3 trial is the latest fallout from U.S. regulators’ recent moves to closely evaluate a class of drugs called PI3 kinase inhibitors. 

    By Dec. 6, 2022
  • A photo of Sekar Kathiresan, CEO of Verve Therapeutics
    Image attribution tooltip
    Seth Babin/BioPharma Dive
    Gene therapy safety

    Verve shares slide after company reveals details on FDA trial hold

    In a letter to the biotech, the regulator asked for more information on its gene editing medicine for heart disease as well as on its potential risks.

    By Dec. 6, 2022
  • A photo of a sign showing the Food and Drug Administration logo
    Image attribution tooltip
    Sarah Silbiger via Getty Images

    Rigel wins US approval of rival drug to Servier leukemia treatment

    The approval gives Rigel, a biotech that’s been around since the mid-1990s, its second marketed medicine and a competitor to Servier’s Tibsovo.

    By Dec. 2, 2022
  • A sign for the Food And Drug Administration is seen outside of the headquarters on July 20, 2020, in White Oak, Maryland.
    Image attribution tooltip
    Sarah Silbiger via Getty Images

    FDA approves first microbiota-based treatment

    The regulatory OK, a milestone for microbiome-based drug research, is for a medicine from Ferring Pharma that treats a recurrent type of gut infection.

    By Dec. 1, 2022
  • Roche Pharmaceutical Group's office building in Shanghai, China
    Image attribution tooltip
    iStock via Getty Images

    Roche pulls Tecentriq in bladder cancer, completing sweep of ‘dangling’ accelerated approvals

    The pharma will no longer market the immunotherapy in the U.S. for urothelial carcinoma, the indication for which the drug was first approved six years ago.

    By Nov. 29, 2022
  • A photo of a sign showing the Food and Drug Administration logo
    Image attribution tooltip
    Sarah Silbiger via Getty Images

    Spectrum to lay off R&D staff after FDA drug rejection

    The company will cut its R&D workforce by 75% and discontinue development of its experimental lung cancer drug poziotinib.

    By Nov. 28, 2022
  • A photograph of a Sarepta building in Boston, MA
    Image attribution tooltip
    Courtesy of Sarepta

    FDA grants speedy review to Sarepta’s Duchenne gene therapy

    The agency will decide on an accelerated approval of Sarepta’s treatment by May 29, months before results are expected from a potentially confirmatory Phase 3 trial.

    By Nov. 28, 2022
  • An illustration of red blood cells
    Image attribution tooltip
    ismagilov via Getty Images

    FDA approves first gene therapy for hemophilia B

    The one-time treatment, which is for the less common “B” form of the bleeding disorder, will be sold in the U.S. by maker CSL for $3.5 million per infusion. 

    By Updated Nov. 23, 2022
  • A photo of a building showing a GSK sign in London.
    Image attribution tooltip
    Courtesy of GSK

    GSK to pull blood cancer drug from US market after study failure

    The British drugmaker has begun the process of withdrawing its multiple myeloma treatment Blenrep following a request from the FDA.

    By Nov. 22, 2022
  • A sign for the Food And Drug Administration is seen outside of the headquarters on July 20, 2020 in White Oak, Maryland.
    Image attribution tooltip
    Sarah Silbiger via Getty Images

    First-of-its-kind Type 1 diabetes drug wins FDA approval

    Provention Bio’s teplizumab is meant to prevent the onset of Type 1 diabetes. To be sold as Tzield, the drug will cost $193,900 for a typical full regimen. 

    By Nov. 18, 2022
  • FDA approves Rezvoglar as second ‘interchangeable’ insulin biosimilar

    Eli Lilly’s long-acting copycat drug, first approved in late 2021, now has a designation that will allow pharmacists to swap it for Sanofi’s Lantus.

    By Nov. 18, 2022
  • A photo of a sign showing the Food and Drug Administration logo
    Image attribution tooltip
    Sarah Silbiger via Getty Images

    FDA panel votes in favor of Ardelyx’s once-rejected kidney disease drug

    The recommendation represents a surprising turnaround for Ardelyx’s drug, which the FDA put before an advisory committee only after the biotech appealed its rejection last year.

    By Kristin Jensen • Nov. 17, 2022
  • Image attribution tooltip
    Jacob Bell

    For ImmunoGen, persistence pays off as FDA clears ovarian cancer drug

    The approval makes Elahere the first wholly owned medicine the biotech has brought to market in its lengthy history.

    By Nov. 15, 2022
  • Colorized scanning electron micrograph of a VERO E6 cell heavily infected with SARS-COV-2 virus particles, isolated from a patient sample.
    Image attribution tooltip
    National Institute of Allergy and Infectious Diseases. (2020). "Novel Coronavirus SARS-CoV-2" [Micrograph]. Retrieved from Flickr.

    Moderna data supports use of omicron booster over original vaccine

    New results show the two-pronged booster the FDA cleared in August sparks a stronger immune response against omicron and its subvariants than Moderna’s original shot.

    By Nov. 14, 2022
  • GlaxoSmithKline CEO Emma Walmsley
    Image attribution tooltip
    Courtesy of GSK Flickr page

    Under FDA pressure, GSK limits use of ovarian cancer drug

    The drugmaker’s decision is the latest fallout from safety concerns that have emerged in testing of so-called PARP inhibitors, resulting in withdrawals by Merck & Co., AstraZeneca and Clovis Oncology. 

    By Nov. 11, 2022
  • A photo of Regeneron's Tarrytown, NY headquarters.
    Image attribution tooltip
    Regeneron

    Regeneron wins broader US use of cancer immunotherapy

    The FDA cleared Libtayo and chemotherapy for use in a broader group of lung cancer patients, a step forward in the company’s plan to compete with rivals Merck and Bristol Myers.

    By Kristin Jensen • Nov. 9, 2022
  • A photo of Sekar Kathiresan, CEO of Verve Therapeutics
    Image attribution tooltip
    Seth Babin/BioPharma Dive
    Gene editing

    FDA halts Verve plans to test gene editing therapy for heart disease in US

    Verve didn’t say what led to the FDA’s decision, but claimed it hasn’t observed any safety issues in an ongoing trial in New Zealand and the U.K, where enrollment will continue.

    By Nov. 7, 2022
  • A window with the logo for Amicus Therapeutics.
    Image attribution tooltip
    Amicus Therapeutics

    FDA again delays review of Amicus rare disease drug

    For the second time this year, the agency has put off a decision on Amicus' therapy for Pompe disease. European regulators are also reviewing the treatment and could soon issue an opinion.

    By Oct. 31, 2022
  • Wide shot of a confident Muslim doctor meeting with healthcare professional team.
    Image attribution tooltip
    RoosterHD via Getty Images
    Sponsored by Worldwide Clinical Trials

    What the FDA’s guidance on diversity means for rare disease sponsors

    Bringing more diversity to clinical trials is a slow process and it takes time to get right. Learn how Worldwide Clinical Trials can diversify the reach of your orphan drug trial.

    Oct. 31, 2022
  • An illustration of red blood cells
    Image attribution tooltip
    ismagilov via Getty Images

    FDA advisers split vote on GSK kidney disease drug, complicating regulatory path

    The anemia pill could become the first drug of its kind to avoid a rejection from U.S. regulators. But an expert panel only supported its use in patients on dialysis, limiting its potential market.

    By Kristin Jensen • Oct. 27, 2022
  • Image attribution tooltip
    Sarah Silbiger via Getty Images

    Speedy FDA approvals in focus as agency weighs withdrawal of preterm birth drug

    The FDA will soon decide whether to pull Covis’ Makena from the market, more than three years after its confirmatory study failed. The delay highlights the need for reforms to the accelerated approval program, critics say.

    By , Oct. 21, 2022
  • A photograph of the exterior of the Food and Drug Administration headquarters in Maryland.
    Image attribution tooltip
    Sarah Silbiger via Getty Images

    FDA advisers back withdrawal of controversial drug for preterm birth

    A committee of independent experts voted 14-1 that the agency shouldn’t allow the treatment from Covis Pharma to remain on the market while further testing is conducted.

    By Updated Oct. 19, 2022
  • A photo of a sign showing the Food and Drug Administration logo
    Image attribution tooltip
    Sarah Silbiger via Getty Images

    FDA opens case to withdraw controversial drug for preterm births

    Beginning a high-stakes advisory meeting, CDER head Patrizia Cavazzoni said that Covis Pharma’s drug is ineffective and should not remain on the market.

    By Oct. 17, 2022
  • A photo of FDA CBER Director Peter Marks delivering remarks at a public workshop on March 3, 2020.
    Image attribution tooltip
    Ermath, Michael. (2020). "Individualized Therapies Workshop" [Photograph]. Retrieved from Flickr.

    ‘We have to find a way’: FDA seeks solutions to aid bespoke gene therapy

    Gene therapies could help treat many ultra-rare diseases. But they may not get developed if drugmakers can’t build a sustainable business around them, CBER director Peter Marks said at a conference. 

    By Oct. 13, 2022
  • Image attribution tooltip
    Sarah Silbiger via Getty Images

    Omicron boosters from Pfizer, Moderna cleared by FDA for younger children

    Pfizer's reformulated vaccine is now authorized for use in children at least 5 years of age, while Moderna's will be available for kids as young as 6.

    By Oct. 12, 2022